<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxins (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Toxins (Basel)</journal-id><journal-id journal-id-type="publisher-id">toxins</journal-id><journal-title-group><journal-title>Toxins</journal-title></journal-title-group><issn pub-type="epub">2072-6651</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39998072</article-id><article-id pub-id-type="pmc">PMC11860530</article-id>
<article-id pub-id-type="doi">10.3390/toxins17020055</article-id><article-id pub-id-type="publisher-id">toxins-17-00055</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Single-Chain Variable Fragments: Targeting Snake Venom Phospholipase A<sub>2</sub> and Serine Protease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0740-8028</contrib-id><name><surname>Jia</surname><given-names>Ying</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="c1-toxins-17-00055" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Garcia</surname><given-names>Ariane</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib><contrib contrib-type="author"><name><surname>Reyes</surname><given-names>Elizabeth</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role></contrib></contrib-group><aff id="af1-toxins-17-00055">School of Integrative Biological and Chemical Sciences, University of Texas Rio Grande Valley, Brownsville, TX 78520, USA; <email>ariane.garcia@utrgv.edu</email> (A.G.); <email>elizabeth.reyes@utrgv.edu</email> (E.R.)</aff><author-notes><corresp id="c1-toxins-17-00055"><label>*</label>Correspondence: <email>ying.jia@utrgv.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>55</elocation-id><history><date date-type="received"><day>27</day><month>11</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Snakebite is a critical global public health issue, causing substantial mortality and morbidity, particularly in tropical and subtropical regions. The development of innovative antivenoms targeting snake venom toxins is therefore of paramount importance. In this study, we adopted an epitope-directed approach to design three degenerate 15-mer peptides based on amino acid sequence alignments of snake venom phospholipase A<sub>2</sub>s (PLA<sub>2</sub>s) and snake venom serine proteases (SVSPs) from snake (<italic toggle="yes">Crotalus atrox</italic>). By leveraging their immunogenic and inhibitory profiles, these peptides were specifically designed to target the Asp49 and Lys49 variants of PLA<sub>2</sub> and SVSP toxins. Groups of five mice were immunized with each peptide, and IgG mRNA was subsequently extracted from peripheral blood mononuclear cells (PBMCs) and spleen lymphocytes of the top three responders. The extracted mRNA was reverse-transcribed into complementary DNA (cDNA), and the variable regions of the IgG heavy and kappa chains were amplified using polymerase chain reaction (PCR). These amplified regions were then linked with a 66-nucleotide spacer to construct single-chain variable fragments (scFvs). Sequence analysis of 48 randomly selected plasmids from each PLA<sub>2</sub> and SVSP scFv library revealed that over 80% contained scFv sequences with notable diversity observed in the complementarity-determining regions (CDRs), particularly CDR3. Enzyme-linked immunosorbent assay (ELISA) results demonstrated that the SP peptide elicited a broader immune response in mice compared to the Asp49 peptide, implying the strong immunogenicity of the SP peptide. These scFvs represent a promising foundation for the development of recombinant human monoclonal antibodies targeting snake PLA<sub>2</sub> and SVSP toxins, providing a potential therapeutic strategy for the treatment of snakebites.</p></abstract><kwd-group><kwd>snakebite</kwd><kwd>PLA<sub>2</sub></kwd><kwd>serine protease</kwd><kwd>peptide</kwd><kwd>immunogenicity</kwd><kwd>single-chain variable fragment</kwd><kwd>immunoglobulin G</kwd></kwd-group><funding-group><award-group><funding-source>NIH-NINDS</funding-source><award-id>R15NS128563</award-id></award-group><funding-statement>This research was supported by NIH-NINDS, grant number R15NS128563.</funding-statement></funding-group></article-meta><notes notes-type="Key Contribution"><title>Key Contribution</title><p>Developed an epitope-directed approach for producing antibody fragments targeting the principal snake toxins for the treatment of snakebites.</p></notes></front><body><sec sec-type="intro" id="sec1-toxins-17-00055"><title>1. Introduction</title><p>Snakebite is a significant global public health concern, leading to high rates of mortality and morbidity, particularly in tropical and subtropical regions. The World Health Organization (WHO) has recognized the severity of the issue and classified snakebite envenomation as a category A neglected tropical disease (NTD) [<xref rid="B1-toxins-17-00055" ref-type="bibr">1</xref>,<xref rid="B2-toxins-17-00055" ref-type="bibr">2</xref>]. Current strategies for snakebite management primarily rely on antivenoms, which are polyclonal antibody-based therapeutics derived from animal serum; however, these polyclonal antivenoms face notable limitations, especially in addressing the wide variability in venom composition across different snake species, which complicates the development of effective treatments. Despite the complexity of snake venoms, the majority of medically significant venom toxins belong to a limited number of toxin families [<xref rid="B3-toxins-17-00055" ref-type="bibr">3</xref>,<xref rid="B4-toxins-17-00055" ref-type="bibr">4</xref>,<xref rid="B5-toxins-17-00055" ref-type="bibr">5</xref>]. The predominant venom toxins in the three major recognized and medically important snake families, Elapidae, Viperidae, and Crotalidae, include phospholipase A<sub>2</sub> (PLA<sub>2</sub>), snake venom metalloproteinase (SVMP), snake venom serine protease (SVSP), and three-finger toxin (3FTx) [<xref rid="B6-toxins-17-00055" ref-type="bibr">6</xref>]. Among these, the broadly neutralizing antibodies targeting 3FTx in elapid snakes have been extensively developed [<xref rid="B7-toxins-17-00055" ref-type="bibr">7</xref>,<xref rid="B8-toxins-17-00055" ref-type="bibr">8</xref>,<xref rid="B9-toxins-17-00055" ref-type="bibr">9</xref>]. To explore alternative therapeutic approaches, this research focuses on developing single-chain variable fragment (scFv) antibodies specifically targeting PLA<sub>2</sub> and SVSP toxins.</p><p>The scFv is an engineered antibody fragment comprising the variable regions of the heavy (V<sub>H</sub>) and light (V<sub>L</sub>) chains of IgG antibody, linked by a short, flexible peptide typically composed of glycine and serine residues. This linker allows the V<sub>H</sub> and V<sub>L</sub> domains to fold into a functional antigen-binding site while increasing solubility through dispersed hydrophilic residues [<xref rid="B10-toxins-17-00055" ref-type="bibr">10</xref>]. Both V<sub>L</sub>-linker-V<sub>H</sub> and V<sub>H</sub>-linker-V<sub>L</sub> configurations are capable of forming functional scFvs, though individual scFvs may exhibit enhanced performance in one configuration over the others [<xref rid="B11-toxins-17-00055" ref-type="bibr">11</xref>]. Due to their high specificity and affinity, low immunogenicity, ease of engineering, scalability, and adaptability to diverse platforms, scFvs have gained wide application in medical, diagnostic, and research fields. For example, their unique structural and functional advantages over full-length monoclonal antibodies have positioned scFvs as critical tools in cancer diagnostics and therapeutics [<xref rid="B12-toxins-17-00055" ref-type="bibr">12</xref>,<xref rid="B13-toxins-17-00055" ref-type="bibr">13</xref>]. Remarkably, scFvs account for approximately 35% of all antibody fragments currently in clinical evaluation for various cancers, including breast, lung, and hematologic malignancies [<xref rid="B14-toxins-17-00055" ref-type="bibr">14</xref>,<xref rid="B15-toxins-17-00055" ref-type="bibr">15</xref>]. Clinically, the small size of scFvs confers advantages such as rapid clearance from blood, ideal for imaging applications, and superior solid tissue penetration, enhancing their utility in therapeutic and imaging contexts [<xref rid="B16-toxins-17-00055" ref-type="bibr">16</xref>]. Additionally, scFvs are less immunogenic in vivo due to the absence of an Fc region [<xref rid="B17-toxins-17-00055" ref-type="bibr">17</xref>,<xref rid="B18-toxins-17-00055" ref-type="bibr">18</xref>]. Their versatility is further demonstrated by their ability to be conjugated with radionuclides or cytotoxic drugs, enabling precision-targeted therapies that minimize off-target effects [<xref rid="B17-toxins-17-00055" ref-type="bibr">17</xref>]. However, scFvs also present challenges, including reduced long-term stability, lower affinities compared to full-length antibodies, and a propensity for aggregation due to their small size [<xref rid="B18-toxins-17-00055" ref-type="bibr">18</xref>]. For instance, their rapid clearance from circulation, with a half-life of 0.5&#x02013;2 h, limits their retention at target sites [<xref rid="B13-toxins-17-00055" ref-type="bibr">13</xref>]. Despite these limitations, this study explores the potential of scFvs targeting PLA<sub>2</sub> and SVSP from the venom of the western diamondback rattlesnake (<italic toggle="yes">Crotalus atrox</italic>).</p><p>The western diamondback rattlesnake (<italic toggle="yes">C. atrox</italic>), a prominent member of the Crotalidae family, is widely distributed across North America and is a leading cause of snakebite fatalities in northern Mexico and the second highest number in the United States [<xref rid="B19-toxins-17-00055" ref-type="bibr">19</xref>]. More than 70% of adult <italic toggle="yes">C. atrox</italic> venom comprises PLA<sub>2</sub>, SVMP, and SVSP [<xref rid="B20-toxins-17-00055" ref-type="bibr">20</xref>]. Accordingly, this study utilizes the primary amino acid sequences of PLA<sub>2</sub> and SVSP from <italic toggle="yes">C. atrox</italic> [<xref rid="B21-toxins-17-00055" ref-type="bibr">21</xref>] to design toxin-targeting peptides. PLA<sub>2</sub>s are a key venom toxin implicated in tissue damage and exhibit diverse pathophysiological effects, including hemorrhagic, myotoxic, hypotensive, presynaptic, cardiotoxic, hemolytic, and anticoagulant activities, mediated through both catalytic and non-catalytic mechanisms [<xref rid="B22-toxins-17-00055" ref-type="bibr">22</xref>,<xref rid="B23-toxins-17-00055" ref-type="bibr">23</xref>]. PLA<sub>2</sub> constitutes more than 7% of <italic toggle="yes">C. atrox</italic> venom, with at least two distinct transcripts identified in its venom and venom glands [<xref rid="B20-toxins-17-00055" ref-type="bibr">20</xref>,<xref rid="B21-toxins-17-00055" ref-type="bibr">21</xref>,<xref rid="B24-toxins-17-00055" ref-type="bibr">24</xref>]. Similarly, SVSPs, prevalent in viperid and crotalid venoms, disrupt hemostatic balance by enzymatically targeting coagulation, fibrinolytic, and kallikrein&#x02013;kinin systems [<xref rid="B25-toxins-17-00055" ref-type="bibr">25</xref>]. These proteolytic enzymes, which feature the classical Ser-His-Asp catalytic triad [<xref rid="B26-toxins-17-00055" ref-type="bibr">26</xref>], possess hemostatic and hemorrhagic effects [<xref rid="B27-toxins-17-00055" ref-type="bibr">27</xref>,<xref rid="B28-toxins-17-00055" ref-type="bibr">28</xref>]. Immunoreactivity studies, such as those by Madrigal et al. [<xref rid="B29-toxins-17-00055" ref-type="bibr">29</xref>], have identified promising immunogenic peptides derived from SVSP.</p><p>To develop broadly neutralizing antivenoms, this research employs the primary amino acid sequences of Asp49 and Lys49 PLA<sub>2</sub> isoforms and SVSP from <italic toggle="yes">C. atrox</italic> as templates for scFv design, synthesis, and immunization. This approach aims to identify potent interactions between IgG variable regions and major venom toxins, ultimately facilitating the development of recombinant oligoclonal antibodies to neutralize snake venom toxins effectively.</p></sec><sec sec-type="results" id="sec2-toxins-17-00055"><title>2. Results and Discussion</title><sec id="sec2dot1-toxins-17-00055"><title>2.1. Peptide Design and Synthesis</title><p>We utilized the amino acid sequences of two mature PLA<sub>2</sub> isoforms, Lys49 and Asp49, cloned from <italic toggle="yes">C. atrox</italic> venom glands. These sequences are identical to NCBI entries Q8UVZ7 and APD70896, respectively. Using the online epitope prediction tool BepiPred-3.0 [<xref rid="B30-toxins-17-00055" ref-type="bibr">30</xref>], we identified four major discontinuous antigenic epitopes for each PLA<sub>2</sub> protein (<xref rid="toxins-17-00055-f001" ref-type="fig">Figure 1</xref>A,B). Among these, only the cationic C-terminal region of the Lys49 PLA<sub>2</sub> protein, comprising 13 amino acid residues (KKYRYYLKPLCKK), is associated with its myotoxic activity [<xref rid="B31-toxins-17-00055" ref-type="bibr">31</xref>]. Specifically, the residue Tyr117 and the positively charged Lys122, particularly Lys122, enhance the affinity for fatty acid head groups, thereby eliciting myotoxic effects [<xref rid="B32-toxins-17-00055" ref-type="bibr">32</xref>,<xref rid="B33-toxins-17-00055" ref-type="bibr">33</xref>]. In contrast, the Asp49 PLA<sub>2</sub> isoform exhibits an N-terminal peptide (NLLQFNKMIKIMTKK) with both immunogenic and neutralization properties [<xref rid="B34-toxins-17-00055" ref-type="bibr">34</xref>,<xref rid="B35-toxins-17-00055" ref-type="bibr">35</xref>]. Residues such as Leu2, Phe5, and Ile9 within this region are critical for substrate interactions [<xref rid="B36-toxins-17-00055" ref-type="bibr">36</xref>]. These two epitopes are surface-exposed and accessible in the AlphaFold-simulated 3D structures (<xref rid="toxins-17-00055-f001" ref-type="fig">Figure 1</xref>C,D). We consequently selected these segments, referred to as PLA<sub>2</sub>a for Lys49 and PLA<sub>2</sub>b for Asp49, for further peptide design. To develop degenerate peptides for potential broad-spectrum scFvs targeting diverse snake venom PLA<sub>2</sub>s, we conducted multiple sequence alignments using PLA<sub>2</sub> sequences from 75 snake species across the Elapidae, Crotalidae, and Viperidae families. The regions corresponding to PLA<sub>2</sub>a and PLA<sub>2</sub>b across these sequences were further analyzed to identify the conserved amino acids, after which the final degenerate peptides were designed with slight modifications, such as substituting &#x0201c;Cys&#x0201d; with &#x0201c;Ser&#x0201d; and incorporating &#x0201c;Tyr&#x0201d; residues in peptides lacking aromatic amino acids, to prevent disulfide bond formation and facilitate conjugation. A similar approach was applied to identify a 15-amino acid peptide, termed SP, from <italic toggle="yes">C. atrox</italic> serine proteases (SVSPs) (<xref rid="toxins-17-00055-f002" ref-type="fig">Figure 2</xref>). The SVSP sequence matched 100% with NCBI entry AUS82489. We conducted a BLAST search using the SVSP sequence and performed multiple alignments with SVSP sequences from 30 snake species to identify conserved residues (<xref rid="toxins-17-00055-f003" ref-type="fig">Figure 3</xref>). This 15-mer peptide was then slightly modified using the same strategy for PLA<sub>2</sub> and finalized for immunization (<xref rid="toxins-17-00055-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec2dot2-toxins-17-00055"><title>2.2. Animal Immunization</title><p>Two groups of five mice were immunized with either a mixture of Lys49 and Asp49 peptides or with SP peptide alone, and serum titers were individually evaluated using an enzyme-linked immunosorbent assay (ELISA) against the corresponding peptide. Overall, the peptide Asp49 (NLLQFNKMIKEETGK) derived from the Asp49 PLA<sub>2</sub> enzyme and SP (LQGGKDTSHYDSGGP) from serine protease elicited similar immune responses, both of which were stronger than the response to Lys49 (YNKKYKIYLKFFSKK) from the Lys49 PLA<sub>2</sub> protein (<xref rid="toxins-17-00055-f004" ref-type="fig">Figure 4</xref>). Furthermore, all mice displayed comparable immunoreactivity to each peptide, while mice M1, M4, and M5 in each group showed slightly stronger immune responses (<xref rid="toxins-17-00055-f004" ref-type="fig">Figure 4</xref>). Consequently, these mice (M1, M4, and M5) were selected for PBMC and lymphocyte isolation.</p></sec><sec id="sec2dot3-toxins-17-00055"><title>2.3. Characterization of scFv</title><p>The scFvs generated through phage display technology have been extensively utilized to develop effective reagents for both therapeutic and diagnostic applications [<xref rid="B37-toxins-17-00055" ref-type="bibr">37</xref>,<xref rid="B38-toxins-17-00055" ref-type="bibr">38</xref>]. However, phage display experiments are not only time-consuming and labor-intensive but also present significant challenges, including limited binding affinity and the generation of false positives [<xref rid="B39-toxins-17-00055" ref-type="bibr">39</xref>,<xref rid="B40-toxins-17-00055" ref-type="bibr">40</xref>]. These limitations often necessitate specialized technical expertise [<xref rid="B41-toxins-17-00055" ref-type="bibr">41</xref>,<xref rid="B42-toxins-17-00055" ref-type="bibr">42</xref>]. In contrast, our streamlined procedure for generating and screening scFv clones provides a renewable resource characterized by versatility, scalability, and consistency. Furthermore, harnessing the advantages of scFvs allows us to deepen our understanding of toxin&#x02013;antibody interactions and explore novel pathways for the development of therapeutic antivenoms. Therefore, using degenerate primers (<xref rid="toxins-17-00055-t001" ref-type="table">Table 1</xref>), we successfully amplified the variable regions of both the heavy and kappa light chains from IgG cDNA derived from PLA<sub>2</sub>- and SP-peptide-immunized samples. In BALB/c mice, over 95% of light chains are kappa, with less than 5% being lambda [<xref rid="B43-toxins-17-00055" ref-type="bibr">43</xref>]. Therefore, this study focused exclusively on the kappa light chain. The amplified variable regions were approximately 350 bp for the heavy chain and 400 bp for the kappa chain (<xref rid="toxins-17-00055-f005" ref-type="fig">Figure 5</xref>A). These regions were subsequently ligated via a 66 bp double-stranded DNA fragment encoding a peptide linker (VSSGGGGSGGGGSGGGGSDIEL) to produce scFvs in the configuration heavy-linker-kappa for both PLA<sub>2</sub> and SP, yielding scFvs of approximately 810 bp (<xref rid="toxins-17-00055-f005" ref-type="fig">Figure 5</xref>B). The scFv constructs for PLA<sub>2</sub> and SP were ligated into a GST-tagged expression vector (pEGX-4T) and introduced into <italic toggle="yes">E. coli</italic> BL21 cells, generating scFv libraries with titers of 1.1 &#x000d7; 10<sup>7</sup> cfu/mL for PLA<sub>2</sub> and 3.5 &#x000d7; 10<sup>7</sup> cfu/mL for SP.</p><p>To evaluate the quality of the libraries, 48 clones were randomly selected from each library, and their inserts were amplified. The results showed that 84% of the PLA<sub>2</sub> scFv library clones and 90% of the SP scFv library clones contained inserts (<xref rid="toxins-17-00055-f005" ref-type="fig">Figure 5</xref>C,D). These clones were further sequenced, and their affinities to peptides were assessed using the ELISA method. In the sequenced 48 clones of the PLA<sub>2</sub> scFv library, 37 sequences encoded mouse heavy and light chains, including 7 perfect sequences (<xref rid="toxins-17-00055-f006" ref-type="fig">Figure 6</xref>) and 30 sequences requiring editing based on database comparisons and trace file analysis, while the remaining sequences were unreadable. Each of the 37 PLA<sub>2</sub> scFv sequences was unique, with differences of more than three amino acids. In the sequenced 48 clones of the SP scFv library, 38 sequences encoded heavy and light chains, comprising 10 perfect sequences (<xref rid="toxins-17-00055-f006" ref-type="fig">Figure 6</xref>) and 28 requiring editing, while the rest were unreadable. Among the SP scFv sequences, four were identified, with two being identical, while only two redundant clones were found between the sequenced 48 clones in the PLA<sub>2</sub> and SP scFv libraries.</p><p>Each of the two variable domains of scFv contains three hypervariable or complementarity-determining regions (CDRs) interlinked by framework regions (FRs) (<xref rid="toxins-17-00055-f006" ref-type="fig">Figure 6</xref>). The CDRs of the heavy chain (V<sub>H</sub>) and light chain (V<sub>L</sub>) were identified following the method described by Kabat et al. [<xref rid="B44-toxins-17-00055" ref-type="bibr">44</xref>]. The CDRs are primarily responsible for antigen binding, with their structures complementing specific epitopes. In contrast, the FRs serve as scaffolds with minimal variability compared to the CDRs. Among the CDRs, CDR3 in both the heavy and light (kappa) chains exhibit greater diversity than CDR1 and CDR2 (<xref rid="toxins-17-00055-f006" ref-type="fig">Figure 6</xref>). Wilson et al. [<xref rid="B45-toxins-17-00055" ref-type="bibr">45</xref>] also demonstrated that the contribution of each CDR to antigen binding varies, with the heavy chain CDR3 playing a pivotal role by contributing 29% to lineage specificity, whereas CDR2L contributes only 4%.</p><p>To evaluate whether the obtained scFv clones recognize PLA<sub>2</sub> and SP peptides, each of the 48 sequenced clones targeting PLA<sub>2</sub> and SP was tested for interactions with their respective peptides. ELISA results (<xref rid="toxins-17-00055-f007" ref-type="fig">Figure 7</xref>) revealed that only three PLA<sub>2</sub> scFv clones interacted with Asp49 peptide, while at least nine SP scFv clones bound to SP peptide. These findings suggest that the SP peptide elicited a broader immune response in mice compared to the Asp49 peptide. However, there was no significant difference in binding affinity between the scFv clones for the Asp49 and SP peptides (<xref rid="toxins-17-00055-f007" ref-type="fig">Figure 7</xref>C). Additionally, we detected interactions of the GST tag only with Asp49, Lys49, and SP peptides, and no interactions were observed. Further screening of the scFv libraries using high-stringent washing methods is planned to identify clones with the highest binding affinities. These selected clones will subsequently be analyzed for their toxin-inhibitory activity in follow-up experiments.</p></sec></sec><sec sec-type="conclusions" id="sec3-toxins-17-00055"><title>3. Conclusions</title><p>Snakebite envenomation remains a significant public health issue, particularly in tropical regions. This research project explores an alternative approach to snakebite treatment by developing scFvs targeting the major snake venom toxins. We successfully produced scFvs against snake venom PLA<sub>2</sub> and SVSP, two major venom components. Unlike polyclonal antibodies or hybridoma-derived monoclonal antibodies, scFvs offer the advantage of genetic manipulability, enabling improved specificity and affinity while also reducing production costs. In subsequent experiments, we plan to screen scFv libraries against individual peptide targets, identify high-affinity interactions, and evaluate the toxin-neutralizing capabilities of these scFvs against native PLA<sub>2</sub> and SVSP isolated from the crude venom of various snake species. Ultimately, our goal is to generate recombinant human monoclonal antibodies to develop a broad-spectrum oligoclonal antibody therapy effective against a wide range of snake venoms.</p></sec><sec id="sec4-toxins-17-00055"><title>4. Materials and Methods</title><sec id="sec4dot1-toxins-17-00055"><title>4.1. Peptide Design</title><p>The venom of adult <italic toggle="yes">C. atrox</italic> comprises more than 7% PLA<sub>2</sub> [<xref rid="B20-toxins-17-00055" ref-type="bibr">20</xref>] with at least two distinct transcripts encoding PLA<sub>2</sub> proteins, Asp49 and Lys49 isoforms, identified in the venom glands and crude venom [<xref rid="B21-toxins-17-00055" ref-type="bibr">21</xref>,<xref rid="B24-toxins-17-00055" ref-type="bibr">24</xref>]. The epitopes for these PLA<sub>2</sub> proteins were predicted using the BepiPred-3.0 tool [<xref rid="B28-toxins-17-00055" ref-type="bibr">28</xref>]. Multiple amino acid sequence alignments were generated using NCBI Protein BLAST and multiple alignment tools. The alignment results were then processed through WebLogo [<xref rid="B46-toxins-17-00055" ref-type="bibr">46</xref>] to assess the amino acid sequence similarity and conservation within the predicted epitope regions, which informed the selection of degenerate peptide sequences for synthesis. To design and synthesize SVSP peptide, we followed the same procedure as that used for PLA<sub>2</sub> peptides. Additionally, the three-dimensional structures of PLA<sub>2</sub>s and SVSP were modeled using AlphaFold [<xref rid="B47-toxins-17-00055" ref-type="bibr">47</xref>] by accessing the Texas Advanced Computing Center (TACC). All peptides were synthesized and verified using mass spectrometry (MS) and high-performance liquid chromatography (HPLC) by Biomatik Corporation (Ontario, Canada) and were used as immunogens for mouse immunization experiments.</p></sec><sec id="sec4dot2-toxins-17-00055"><title>4.2. Animal Immunization</title><p>In collaboration with ProteoGenix (Schiltigheim, France), the animal experiments were conducted following a protocol approved by the University of Texas Rio Grande Valley (UTRGV) Institutional Animal Care and Use Committee (AUP-23-15). BALB/c mice, weighing 18&#x02013;20 g, were acclimatized for one week before the initiation of the experiments. The mice were housed in standard cages under controlled conditions: ambient temperature maintained at approximately 22 &#x000b0;C, relative humidity between 40% and 50%, and a 12-hour light/dark cycle. Food and reverse osmosis water were provided <italic toggle="yes">ad libitum</italic> via an automated water delivery system. For immunization, five mice were used per peptide, with each receiving an initial dose of 0.25 mg of peptide, followed by three booster injections of the same amount. The efficacy of immunization was assessed by evaluating the ability of serum derived from immunized mice to recognize the respective peptides. From the group, three mice showing the strongest immune responses were selected for the isolation of peripheral blood mononuclear cells (PBMCs) and spleen lymphocytes. PBMCs and spleen lymphocytes from mice immunized with Asp49 or Lys49 peptides were pooled to extract IgG mRNA.</p></sec><sec id="sec4dot3-toxins-17-00055"><title>4.3. Enzyme-Linked Immunosorbent Assay</title><p>The ELISA was performed following the protocol described by Slutzki et al. [<xref rid="B48-toxins-17-00055" ref-type="bibr">48</xref>], with modifications as detailed below: (1) A 96-well plate (Thermo Fisher Scientific, Waltham, MA, USA, 439454) was coated with 100 &#x000b5;L of peptide (10 &#x000b5;g/mL) prepared in 1&#x000d7; Boca coating buffer (Thermo Fisher Scientific, Waltham, MA, USA, NC1894485) and incubated overnight at 4 &#x000b0;C. (2) Single-chain variable fragment (scFv) clones were incubated in 1.5 mL tubes containing 1 mL of LB broth supplemented with ampicillin (100 &#x000b5;g/mL) and IPTG (1 mM) at 37 &#x000b0;C for two days with shaking (220 rpm). (3) The peptide-coated 96-well plate was washed three times with 200 &#x000b5;L of 1&#x000d7; PBS buffer, blocked with 150 &#x000b5;L of SuperBlock buffer (Thermo Fisher Scientific, Waltham, MA, USA, 37515) per well for 1 h with shaking, and then rinsed once with 200 &#x000b5;L of 1&#x000d7; PBS buffer. (4) Bacterial cultures from Step (2) were centrifuged, the supernatant discarded, and the cell pellet resuspended in 100 &#x000b5;L of 1&#x000d7; PBS buffer. After this, 10 &#x000b5;L of lysozyme (20 &#x000b5;g/&#x000b5;L) was added, followed by incubation at 37 &#x000b0;C with gentle shaking (100 rpm) for 1 h. Cell debris was then pelleted by centrifugation at top speed for 3 min. (5) A total of 100 &#x000b5;L of the bacterial lysate from Step (4) was added to the prepared 96-well plate from Step (3) and incubated overnight at 4 &#x000b0;C. For immunogenicity tests, sera from the three highest-responder mice were serially diluted (1:2000 to 1:128,000) and added to the 96-well plates. (6) The plate was washed three times with 200 &#x000b5;L of 1&#x000d7; PBS buffer. (7) The wells were incubated with 100 &#x000b5;L of anti-GST primary antibody (Sigma-Aldrich, St. Louis, MO, USA, G7781) diluted 1:10,000 in 5% BSA/TBST for 1.5 h at room temperature with gentle shaking, followed by three washes with 1&#x000d7; TBST buffer. (8) Subsequently, 100 &#x000b5;L of goat anti-rabbit secondary antibody conjugated with HRP (Thermo Fisher Scientific, Waltham, MA, USA, 32460), prepared in a 1:10,000 dilution in 5% BSA/TBST, was added. The plate was incubated with shaking for 1.5 h at room temperature and then washed three times with 1&#x000d7; TBST buffer. (9) A total of 100 &#x000b5;L of TMB-ELISA substrate solution (Thermo Fisher Scientific, Waltham, MA, USA, 34029) was added to each well and incubated in the dark until the solution turned blue (approximately 1 h). (10) The reaction was stopped by adding 100 &#x000b5;L of sulfuric acid buffer (Thermo Fisher Scientific, Waltham, MA, USA, 035663-k2). The absorbance was measured at 450 nm using a plate reader (Accuris Instruments, Edison, NJ, USA. R9610). The ELISA results were analyzed using GraphPad Prism software (version 10.2.3).</p></sec><sec id="sec4dot4-toxins-17-00055"><title>4.4. IgG Complementary DNA Generation</title><p>PBMCs and spleen lymphocytes were promptly isolated from the three most effectively immunized mice, which were euthanized following the UTRGV-approved protocol (AUP-23-15). Total RNA was extracted from the PBMCs and lymphocytes using TRIzo reagent (Thermo Fisher Scientific, Waltham, MA, USA, 15596026). The extracted RNA was subsequently reverse-transcribed into complementary DNA (cDNA) according to the manufacturer&#x02019;s instructions for the Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, MA, USA, K1641).</p></sec><sec id="sec4dot5-toxins-17-00055"><title>4.5. scFv Generation</title><p>To generate single-chain variable fragments (scFvs), we began by extracting DNA sequences encoding mouse immunoglobulin G (IgG) heavy and kappa chains from the NCBI database. Multiple sequence alignments were performed separately for the heavy and kappa chain sequences. Based on these alignments, degenerate primers (<xref rid="toxins-17-00055-t001" ref-type="table">Table 1</xref>) targeting the constant regions of IgG were designed to amplify the variable regions of both the heavy and kappa chains by polymerase chain reaction (PCR). PCR was performed using Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA, F530) with the following setup: after initial denaturation of DNA at 98 &#x000b0;C for 30 s, 35 cycles of amplification were performed, including denaturation at 98 &#x000b0;C for 10 s, annealing at 55 &#x000b0;C or 58 &#x000b0;C (55 &#x000b0;C for amplifying V<sub>H</sub> and V<sub>L</sub>, while 58 &#x000b0;C for amplifying scFv) for 30 s, and extension at 72 &#x000b0;C for 1 min, followed by further extension for 10 min at 72 &#x000b0;C. PCR products, visualized in 1.5% agarose gel by staining with SYBR Safe DNA gel stain (Thermo Fisher Scientific, Waltham, MA, USA, S33102), were excised and purified using the GENECLEAN kit (Thermo Fisher Scientific, Waltham, MA, USA, 111001200).</p><p>To link the variable regions, a 66-nucleotide double-stranded linker was synthesized using sequences described by Wang et al. [<xref rid="B49-toxins-17-00055" ref-type="bibr">49</xref>] and Lang et al. [<xref rid="B50-toxins-17-00055" ref-type="bibr">50</xref>]. The variable heavy (V<sub>H</sub>) and variable light (V<sub>L</sub>) chains were joined (V<sub>H</sub>-linker-V<sub>L</sub>) using the In-Fusion Snap Assembly Master Mix (Takara, San Jose, CA, USA, 638947) at the molecular ratio of V<sub>H</sub> to V<sub>L</sub> to linker DNA of approximately 2:2:1. The assembled scFv constructs were directly used to amplify the scFvs by PCR and purified from agarose gels, digested with EcoR I and Xho I, and subsequently ligated into the EcoR I and Xho I sites of the pGEX-4T vector (Addgene, Watertown, MA, USA, 29567) using T4 DNA Ligase (BioLabs, Ipswich, MA, USA, 0202). Finally, the ligation products were transformed into <italic toggle="yes">E. coli</italic> BL21 (DE3) competent cells by electroporation for the generation of scFv libraries.</p></sec></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, Y.J., A.G. and E.R.; methodology, Y.J., A.G. and E.R.; collection of data, Y.J., A.G. and E.R.; analysis, Y.J., A.G. and E.R.; writing&#x02014;original draft preparation, Y.J.; writing&#x02014;review and editing, Y.J., A.G. and E.R.; supervision, Y.J. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>All animal experiments were performed with the approval of the Animal Care and Use Committee of the University of Texas Rio Grande Valley, USA (approval code AUP-23-15; approval date 11 September 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-toxins-17-00055"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chippaux</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Snakebite envenomation turns again into a neglected tropical disease!</article-title><source>J. Venom. Anim. Toxins Incl. Trop. Dis.</source><year>2017</year><volume>23</volume><fpage>38</fpage><pub-id pub-id-type="doi">10.1186/s40409-017-0127-6</pub-id><pub-id pub-id-type="pmid">28804495</pub-id>
</element-citation></ref><ref id="B2-toxins-17-00055"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guti&#x000e9;rrez</surname><given-names>J.M.</given-names></name>
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Habib</surname><given-names>A.G.</given-names></name>
<name><surname>Harrison</surname><given-names>R.A.</given-names></name>
<name><surname>Williams</surname><given-names>D.J.</given-names></name>
</person-group><article-title>Snakebite envenoming</article-title><source>Nat. Rev. Dis. Primers</source><year>2017</year><volume>3</volume><fpage>17063</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2017.63</pub-id><pub-id pub-id-type="pmid">28905944</pub-id>
</element-citation></ref><ref id="B3-toxins-17-00055"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sanz</surname><given-names>L.</given-names></name>
<name><surname>de Freitas-Lima</surname><given-names>L.N.</given-names></name>
<name><surname>Quesada-Bernat</surname><given-names>S.</given-names></name>
<name><surname>Gra&#x000e7;a-De-Souza</surname><given-names>V.K.</given-names></name>
<name><surname>Soares</surname><given-names>A.M.</given-names></name>
<name><surname>Calder&#x000f3;n</surname><given-names>L.d.A.</given-names></name>
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Caldeira</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Comparative Venomics of Brazilian Coral Snakes: <italic toggle="yes">Micrurus frontalis</italic>, <italic toggle="yes">Micrurus spixii spixii</italic>, and <italic toggle="yes">Micrurus surinamensis</italic></article-title><source>Toxicon</source><year>2019</year><volume>166</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2019.05.001</pub-id><pub-id pub-id-type="pmid">31091423</pub-id>
</element-citation></ref><ref id="B4-toxins-17-00055"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Saviola</surname><given-names>A.J.</given-names></name>
<name><surname>Bonilla</surname><given-names>F.</given-names></name>
<name><surname>Sasa</surname><given-names>M.</given-names></name>
<name><surname>Williams</surname><given-names>D.J.</given-names></name>
<name><surname>Undheim</surname><given-names>E.A.B.</given-names></name>
<name><surname>Sunagar</surname><given-names>K.</given-names></name>
<name><surname>Jackson</surname><given-names>T.N.W.</given-names></name>
</person-group><article-title>Mutual enlightenment: A toolbox of concepts and methods for integrating evolutionary and clinical toxinology via snake venomics and contextual stance</article-title><source>Toxicon X</source><year>2021</year><volume>9&#x02013;10</volume><fpage>100070</fpage><pub-id pub-id-type="doi">10.1016/j.toxcx.2021.100070</pub-id></element-citation></ref><ref id="B5-toxins-17-00055"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sunagar</surname><given-names>K.</given-names></name>
<name><surname>Khochare</surname><given-names>S.</given-names></name>
<name><surname>Senji Laxme</surname><given-names>R.R.</given-names></name>
<name><surname>Attarde</surname><given-names>S.</given-names></name>
<name><surname>Dam</surname><given-names>P.</given-names></name>
<name><surname>Suranse</surname><given-names>V.</given-names></name>
<name><surname>Khaire</surname><given-names>A.</given-names></name>
<name><surname>Martin</surname><given-names>G.</given-names></name>
<name><surname>Captain</surname><given-names>A.</given-names></name>
</person-group><article-title>A wolf in another wolf&#x02019;s clothing: Post-genomic regulation dictates venom profiles of medically-important cryptic kraits in India</article-title><source>Toxins</source><year>2021</year><volume>13</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.3390/toxins13010069</pub-id><pub-id pub-id-type="pmid">33477742</pub-id>
</element-citation></ref><ref id="B6-toxins-17-00055"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tasoulis</surname><given-names>T.</given-names></name>
<name><surname>Isbister</surname><given-names>G.K.</given-names></name>
</person-group><article-title>A review and database of snake venom proteomes</article-title><source>Toxins</source><year>2017</year><volume>9</volume><elocation-id>290</elocation-id><pub-id pub-id-type="doi">10.3390/toxins9090290</pub-id><pub-id pub-id-type="pmid">28927001</pub-id>
</element-citation></ref><ref id="B7-toxins-17-00055"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ledsgaard</surname><given-names>L.</given-names></name>
<name><surname>Laustsen</surname><given-names>A.H.</given-names></name>
<name><surname>Pus</surname><given-names>U.</given-names></name>
<name><surname>Wade</surname><given-names>J.</given-names></name>
<name><surname>Villar</surname><given-names>P.</given-names></name>
<name><surname>Boddum</surname><given-names>K.</given-names></name>
<name><surname>Slavny</surname><given-names>P.</given-names></name>
<name><surname>Masters</surname><given-names>E.W.</given-names></name>
<name><surname>Arias</surname><given-names>A.S.</given-names></name>
<name><surname>Oscoz</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>In vitro discovery of a human monoclonal antibody that neutralizes lethality of cobra snake venom</article-title><source>Mabs</source><year>2022</year><volume>14</volume><fpage>2085536</fpage><pub-id pub-id-type="doi">10.1080/19420862.2022.2085536</pub-id><pub-id pub-id-type="pmid">35699567</pub-id>
</element-citation></ref><ref id="B8-toxins-17-00055"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ledsgaard</surname><given-names>L.</given-names></name>
<name><surname>Wade</surname><given-names>J.</given-names></name>
<name><surname>Jenkins</surname><given-names>T.P.</given-names></name>
<name><surname>Boddum</surname><given-names>K.</given-names></name>
<name><surname>Oganesyan</surname><given-names>I.</given-names></name>
<name><surname>Harrison</surname><given-names>J.A.</given-names></name>
<name><surname>Villar</surname><given-names>P.</given-names></name>
<name><surname>Leah</surname><given-names>R.A.</given-names></name>
<name><surname>Zenobi</surname><given-names>R.</given-names></name>
<name><surname>Schoffelen</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Discovery and optimization of a broadly- neutralizing human monoclonal antibody against long-chain &#x003b1;-neurotoxins from snakes</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>682</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36393-4</pub-id><pub-id pub-id-type="pmid">36755049</pub-id>
</element-citation></ref><ref id="B9-toxins-17-00055"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Khalek</surname><given-names>I.S.</given-names></name>
<name><surname>Laxme</surname><given-names>R.R.S.</given-names></name>
<name><surname>Nauyen</surname><given-names>Y.T.K.</given-names></name>
<name><surname>Khochare</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>R.N.</given-names></name>
<name><surname>Woehl</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>J.M.</given-names></name>
<name><surname>Saye-Francisco</surname><given-names>K.</given-names></name>
<name><surname>Kim</surname><given-names>Y.</given-names></name>
<name><surname>Mindrebo</surname><given-names>L.M.</given-names></name>
<etal/>
</person-group><article-title>Synthetic development of a broadly neutralizing antibody against snake venom long-chain &#x003b1;-neurotoxins</article-title><source>Sci. Transl. Med.</source><year>2024</year><volume>16</volume><fpage>735</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adk1867</pub-id></element-citation></ref><ref id="B10-toxins-17-00055"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Monnier</surname><given-names>P.P.</given-names></name>
<name><surname>Vigouroux</surname><given-names>R.J.</given-names></name>
<name><surname>Tassew</surname><given-names>N.G.</given-names></name>
</person-group><article-title>In vivo applications of single chain Fv (variable domain) (scFv) fragments</article-title><source>Antibodies</source><year>2013</year><volume>2</volume><fpage>193</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.3390/antib2020193</pub-id></element-citation></ref><ref id="B11-toxins-17-00055"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sandomenico</surname><given-names>A.</given-names></name>
<name><surname>Sivaccumar</surname><given-names>J.P.</given-names></name>
<name><surname>Ruvo</surname><given-names>M.</given-names></name>
</person-group><article-title>Evolution of <italic toggle="yes">Escherichia coli</italic> Expression System in Producing Antibody Recombinant Fragments</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>6324</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21176324</pub-id><pub-id pub-id-type="pmid">32878291</pub-id>
</element-citation></ref><ref id="B12-toxins-17-00055"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yazaki</surname><given-names>P.J.</given-names></name>
<name><surname>Wu</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Construction and characterization of minibodies for imaging and therapy of colorectal carcinomas</article-title><source>Methods Mol. Biol.</source><year>2003</year><volume>207</volume><fpage>351</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">12412485</pub-id>
</element-citation></ref><ref id="B13-toxins-17-00055"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knowles</surname><given-names>S.M.</given-names></name>
<name><surname>Wu</surname><given-names>A.M.</given-names></name>
</person-group><article-title>Advances in immuno-positron emission tomography: Antibodies for molecular imaging in oncology</article-title><source>J. Clin. Oncol.</source><year>2012</year><volume>30</volume><fpage>3884</fpage><lpage>3892</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.42.4887</pub-id><pub-id pub-id-type="pmid">22987087</pub-id>
</element-citation></ref><ref id="B14-toxins-17-00055"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Holliger</surname><given-names>P.</given-names></name>
<name><surname>Hudson</surname><given-names>P.J.</given-names></name>
</person-group><article-title>Engineered antibody fragments and the rise of single domains</article-title><source>Nat. Biotechnol.</source><year>2005</year><volume>23</volume><fpage>1126</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1038/nbt1142</pub-id><pub-id pub-id-type="pmid">16151406</pub-id>
</element-citation></ref><ref id="B15-toxins-17-00055"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nelson</surname><given-names>A.L.</given-names></name>
<name><surname>Reichert</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Development trends for therapeutic antibody fragments</article-title><source>Nat. Biotechnol.</source><year>2009</year><volume>27</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nbt0409-331</pub-id><pub-id pub-id-type="pmid">19352366</pub-id>
</element-citation></ref><ref id="B16-toxins-17-00055"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yokota</surname><given-names>T.</given-names></name>
<name><surname>Milenic</surname><given-names>D.E.</given-names></name>
<name><surname>Whitlow</surname><given-names>M.</given-names></name>
<name><surname>Schlom</surname><given-names>J.</given-names></name>
</person-group><article-title>Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms</article-title><source>Cancer Res.</source><year>1992</year><volume>52</volume><fpage>3402</fpage><lpage>3408</lpage><pub-id pub-id-type="pmid">1596900</pub-id>
</element-citation></ref><ref id="B17-toxins-17-00055"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmad</surname><given-names>Z.A.</given-names></name>
<name><surname>Yeap</surname><given-names>S.K.</given-names></name>
<name><surname>Ali</surname><given-names>A.M.</given-names></name>
<name><surname>Ho</surname><given-names>W.Y.</given-names></name>
<name><surname>Alitheen</surname><given-names>N.B.M.</given-names></name>
<name><surname>Hamid</surname><given-names>M.</given-names></name>
</person-group><article-title>scFv antibody: Principles and clinical application</article-title><source>Clin. Dev. Immunol.</source><year>2012</year><volume>2012</volume><fpage>980250</fpage><pub-id pub-id-type="doi">10.1155/2012/980250</pub-id><pub-id pub-id-type="pmid">22474489</pub-id>
</element-citation></ref><ref id="B18-toxins-17-00055"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bates</surname><given-names>A.</given-names></name>
<name><surname>Power</surname><given-names>C.A.</given-names></name>
</person-group><article-title>David vs. Goliath: The structure, function, and clinical prospects of antibody fragments</article-title><source>Antibodies</source><year>2019</year><volume>8</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.3390/antib8020028</pub-id><pub-id pub-id-type="pmid">31544834</pub-id>
</element-citation></ref><ref id="B19-toxins-17-00055"><label>19.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>J.A.</given-names></name>
<name><surname>Lamar</surname><given-names>W.W.</given-names></name>
</person-group><source>The Venomous Reptiles of the Western Hemisphere</source><publisher-name>Comstock Publishing Associates</publisher-name><publisher-loc>Ithaca, NY, USA</publisher-loc><year>2004</year></element-citation></ref><ref id="B20-toxins-17-00055"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calvete</surname><given-names>J.J.</given-names></name>
<name><surname>Fasoli</surname><given-names>E.</given-names></name>
<name><surname>Sanz</surname><given-names>L.</given-names></name>
<name><surname>Boschetti</surname><given-names>E.</given-names></name>
<name><surname>Righetti</surname><given-names>P.G.</given-names></name>
</person-group><article-title>Exploring the venom proteome of the western diamondback rattlesnake, <italic toggle="yes">Crotalus atrox</italic>, via snake venomics and combinatorial peptide ligand library approaches</article-title><source>J. Proteome Res.</source><year>2009</year><volume>8</volume><fpage>3055</fpage><lpage>3067</lpage><pub-id pub-id-type="doi">10.1021/pr900249q</pub-id><pub-id pub-id-type="pmid">19371136</pub-id>
</element-citation></ref><ref id="B21-toxins-17-00055"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jia</surname><given-names>Y.</given-names></name>
<name><surname>Lopez</surname><given-names>I.</given-names></name>
<name><surname>Kowalski</surname><given-names>P.</given-names></name>
</person-group><article-title>Toxin transcripts in <italic toggle="yes">Crotalus atrox</italic> venom and in silico structure of toxins</article-title><source>J. Venom Res.</source><year>2020</year><volume>10</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">32774833</pub-id>
</element-citation></ref><ref id="B22-toxins-17-00055"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kini</surname><given-names>R.M.</given-names></name>
<name><surname>Evans</surname><given-names>H.J.</given-names></name>
</person-group><article-title>Structure-function relationships of phospholipases</article-title><source>J. Biol. Chem.</source><year>1987</year><volume>262</volume><fpage>14402</fpage><lpage>14407</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(18)47808-8</pub-id><pub-id pub-id-type="pmid">3117784</pub-id>
</element-citation></ref><ref id="B23-toxins-17-00055"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murakami</surname><given-names>M.</given-names></name>
<name><surname>Kudo</surname><given-names>I.</given-names></name>
</person-group><article-title>Phospholipase A<sub>2</sub></article-title><source>J. Biochem</source><year>2002</year><volume>131</volume><fpage>285</fpage><lpage>292</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a003101</pub-id><pub-id pub-id-type="pmid">11872155</pub-id>
</element-citation></ref><ref id="B24-toxins-17-00055"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vega</surname><given-names>C.</given-names></name>
<name><surname>Jia</surname><given-names>Y.</given-names></name>
</person-group><article-title>Tarantula toxin transcripts and toxin structure prediction by AlphaFold</article-title><source>Chem. Pharm. Res.</source><year>2024</year><volume>6</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.33425/2689-1050.1060</pub-id></element-citation></ref><ref id="B25-toxins-17-00055"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serrano</surname><given-names>S.M.T.</given-names></name>
</person-group><article-title>The long road of research on snake venom serine proteinases</article-title><source>Toxicon</source><year>2013</year><volume>62</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.09.003</pub-id><pub-id pub-id-type="pmid">23010164</pub-id>
</element-citation></ref><ref id="B26-toxins-17-00055"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ekici</surname><given-names>&#x000d6;.D.</given-names></name>
<name><surname>Paetzel</surname><given-names>M.</given-names></name>
<name><surname>Dalbey</surname><given-names>R.E.</given-names></name>
</person-group><article-title>Unconventional serine proteinases: Variations on the catalytic ser/His/Asp triad configuration</article-title><source>Protein Sci.</source><year>2008</year><volume>17</volume><fpage>2023</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1110/ps.035436.108</pub-id><pub-id pub-id-type="pmid">18824507</pub-id>
</element-citation></ref><ref id="B27-toxins-17-00055"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Neurath</surname><given-names>H.</given-names></name>
</person-group><article-title>Evolution of proteolytic enzymes</article-title><source>Science</source><year>1984</year><volume>224</volume><fpage>350</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1126/science.6369538</pub-id><pub-id pub-id-type="pmid">6369538</pub-id>
</element-citation></ref><ref id="B28-toxins-17-00055"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marsh</surname><given-names>N.</given-names></name>
<name><surname>Williams</surname><given-names>V.</given-names></name>
</person-group><article-title>Practical application of snake venom toxins in haemostasis</article-title><source>Toxicon</source><year>2005</year><volume>45</volume><fpage>1171</fpage><lpage>1181</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2005.02.016</pub-id><pub-id pub-id-type="pmid">15922782</pub-id>
</element-citation></ref><ref id="B29-toxins-17-00055"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Madrigal</surname><given-names>M.</given-names></name>
<name><surname>Alape-Gir&#x000f3;n</surname><given-names>A.</given-names></name>
<name><surname>Barboza-Arguedas</surname><given-names>E.</given-names></name>
<name><surname>Aguilar-Ulloa</surname><given-names>W.</given-names></name>
<name><surname>Flores-D&#x000ed;az</surname><given-names>M.</given-names></name>
</person-group><article-title>Identification of B cell recognized linear epitopes in a snake venom serine proteinase from the central American bushmaster Lachesis stenophrys</article-title><source>Toxicon</source><year>2017</year><volume>140</volume><fpage>72</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2017.10.022</pub-id><pub-id pub-id-type="pmid">29111117</pub-id>
</element-citation></ref><ref id="B30-toxins-17-00055"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clifford</surname><given-names>J.N.</given-names></name>
<name><surname>H&#x000f8;ie</surname><given-names>M.H.</given-names></name>
<name><surname>Deleuran</surname><given-names>S.</given-names></name>
<name><surname>Peters</surname><given-names>B.</given-names></name>
<name><surname>Nielsen</surname><given-names>M.</given-names></name>
<name><surname>Marcatili</surname><given-names>P.</given-names></name>
</person-group><article-title>BepiPred-3.0: Improved B-cell epitope prediction using protein language models</article-title><source>Protein Sci.</source><year>2022</year><volume>31</volume><fpage>e4497</fpage><pub-id pub-id-type="doi">10.1002/pro.4497</pub-id><pub-id pub-id-type="pmid">36366745</pub-id>
</element-citation></ref><ref id="B31-toxins-17-00055"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
</person-group><article-title>Identification of linear B-cell epitopes on myotoxin II, a Lys49 phospholipase A<sub>2</sub> homologue from Bothrops asper snake venom</article-title><source>Toxicon</source><year>2012</year><volume>60</volume><fpage>782</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2012.05.028</pub-id><pub-id pub-id-type="pmid">22677805</pub-id>
</element-citation></ref><ref id="B32-toxins-17-00055"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chioato</surname><given-names>L.</given-names></name>
<name><surname>Arag&#x000e3;o</surname><given-names>E.A.</given-names></name>
<name><surname>Ferreira</surname><given-names>T.L.</given-names></name>
<name><surname>de Medeiros</surname><given-names>A.I.</given-names></name>
<name><surname>Faccioli</surname><given-names>L.H.</given-names></name>
<name><surname>Ward</surname><given-names>R.J.</given-names></name>
</person-group><article-title>Mapping of the structural determinants of artificial and biological membrane damaging activities of Lys49 phospholipase A<sub>2</sub> by scanning alanine mutagenesis</article-title><source>Biochim. Biophys. Acta</source><year>2007</year><volume>1768</volume><fpage>1247</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.01.023</pub-id><pub-id pub-id-type="pmid">17346668</pub-id>
</element-citation></ref><ref id="B33-toxins-17-00055"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>C.A.H.</given-names></name>
<name><surname>Borges</surname><given-names>R.J.</given-names></name>
<name><surname>Lomonte</surname><given-names>B.</given-names></name>
<name><surname>Fontes</surname><given-names>M.R.</given-names></name>
</person-group><article-title>A structure-based proposal for a comprehensive myotoxic mechanism of phospholipase A<sub>2</sub>-like proteins from viperid snake venoms</article-title><source>Biochem. Biophys. Acta</source><year>2014</year><volume>12</volume><fpage>2265</fpage><lpage>2276</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2014.09.015</pub-id></element-citation></ref><ref id="B34-toxins-17-00055"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Castro</surname><given-names>K.L.P.</given-names></name>
<name><surname>Lopes-de-Souza</surname><given-names>L.</given-names></name>
<name><surname>de Oliveira</surname><given-names>D.</given-names></name>
<name><surname>Machado-de-&#x000c1;vila</surname><given-names>R.A.</given-names></name>
<name><surname>Paiva</surname><given-names>A.L.B.</given-names></name>
<name><surname>de Freitas</surname><given-names>C.F.</given-names></name>
<name><surname>Ho</surname><given-names>P.L.</given-names></name>
<name><surname>Ch&#x000e1;vez-Ol&#x000f3;rtegui</surname><given-names>C.</given-names></name>
<name><surname>Guerra</surname><given-names>C.</given-names></name>
</person-group><article-title>A combined strategy to improve the development of a coral antivenom against <italic toggle="yes">Micrurus</italic> spp.</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>2422</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.02422</pub-id><pub-id pub-id-type="pmid">31695693</pub-id>
</element-citation></ref><ref id="B35-toxins-17-00055"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Castro</surname><given-names>K.L.</given-names></name>
<name><surname>Duarte</surname><given-names>C.G.</given-names></name>
<name><surname>Ramos</surname><given-names>H.R.</given-names></name>
<name><surname>de Avila</surname><given-names>R.A.M.</given-names></name>
<name><surname>Schneider</surname><given-names>F.S.</given-names></name>
<name><surname>Oliveira</surname><given-names>D.</given-names></name>
<name><surname>Freitas</surname><given-names>C.F.</given-names></name>
<name><surname>Kalapothakis</surname><given-names>E.</given-names></name>
<name><surname>Ho</surname><given-names>P.L.</given-names></name>
<name><surname>Ch&#x000e1;vez-Olortegui</surname><given-names>C.</given-names></name>
</person-group><article-title>Identification and characterization of B-cell epitopes of 3FTx and PLA<sub>2</sub> toxins from <italic toggle="yes">Micrurus corallinus</italic> snake venom</article-title><source>Toxicon</source><year>2015</year><volume>93</volume><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.toxicon.2014.10.015</pub-id><pub-id pub-id-type="pmid">25454319</pub-id>
</element-citation></ref><ref id="B36-toxins-17-00055"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kang</surname><given-names>T.S.</given-names></name>
<name><surname>Georgieva</surname><given-names>D.</given-names></name>
<name><surname>Genov</surname><given-names>N.</given-names></name>
<name><surname>Murakami</surname><given-names>M.T.</given-names></name>
<name><surname>Sinha</surname><given-names>M.</given-names></name>
<name><surname>Kumar</surname><given-names>R.P.</given-names></name>
<name><surname>Kaur</surname><given-names>P.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
<name><surname>Dey</surname><given-names>S.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Enzymatic toxins from snake venom: Structural characterization and mechanism of catalysis</article-title><source>FEBS J.</source><year>2011</year><volume>278</volume><fpage>4544</fpage><lpage>4576</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08115.x</pub-id><pub-id pub-id-type="pmid">21470368</pub-id>
</element-citation></ref><ref id="B37-toxins-17-00055"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>R.</given-names></name>
<name><surname>Means</surname><given-names>N.</given-names></name>
</person-group><article-title>Molecular farming of pharmaceutical proteins</article-title><source>Transgenic Res.</source><year>2000</year><volume>9</volume><fpage>279</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1023/A:1008975123362</pub-id><pub-id pub-id-type="pmid">11131007</pub-id>
</element-citation></ref><ref id="B38-toxins-17-00055"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kanter</surname><given-names>G.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Voloshin</surname><given-names>A.</given-names></name>
<name><surname>Levy</surname><given-names>S.</given-names></name>
<name><surname>Swartz</surname><given-names>J.R.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
</person-group><article-title>Cell-free production of scFv fusion proteins: An efficient approach for personalized lymphoma vaccines</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>3393</fpage><lpage>3399</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-07-030593</pub-id><pub-id pub-id-type="pmid">17164345</pub-id>
</element-citation></ref><ref id="B39-toxins-17-00055"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chung</surname><given-names>D.H.</given-names></name>
<name><surname>Kong</surname><given-names>S.</given-names></name>
<name><surname>Young</surname><given-names>N.J.</given-names></name>
<name><surname>Chuo</surname><given-names>S.-W.</given-names></name>
<name><surname>Shiah</surname><given-names>J.V.</given-names></name>
<name><surname>Connelly</surname><given-names>E.J.</given-names></name>
<name><surname>Rohweder</surname><given-names>P.J.</given-names></name>
<name><surname>Born</surname><given-names>A.</given-names></name>
<name><surname>Manglik</surname><given-names>A.</given-names></name>
<name><surname>Grandis</surname><given-names>J.R.</given-names></name>
<etal/>
</person-group><article-title>Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets</article-title><source>Commun. Biol.</source><year>2023</year><volume>6</volume><elocation-id>1036</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-023-05390-0</pub-id><pub-id pub-id-type="pmid">37828150</pub-id>
</element-citation></ref><ref id="B40-toxins-17-00055"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keyser</surname><given-names>P.D.</given-names></name>
<name><surname>Kalichuk</surname><given-names>V.</given-names></name>
<name><surname>Z&#x000f6;gg</surname><given-names>T.</given-names></name>
<name><surname>Wohlk&#x000f6;nig</surname><given-names>A.</given-names></name>
<name><surname>Schenck</surname><given-names>S.</given-names></name>
<name><surname>Brunner</surname><given-names>J.</given-names></name>
<name><surname>Pardon</surname><given-names>E.</given-names></name>
<name><surname>Steyaert</surname><given-names>J.</given-names></name>
</person-group><article-title>A biosensor-based phage display selection method for automated, high-throughput Nanobody discovery</article-title><source>Biosens. Bioelectron.</source><year>2024</year><volume>271</volume><elocation-id>116951</elocation-id><pub-id pub-id-type="doi">10.1016/j.bios.2024.116951</pub-id><pub-id pub-id-type="pmid">39631210</pub-id>
</element-citation></ref><ref id="B41-toxins-17-00055"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ledsgaad</surname><given-names>L.</given-names></name>
<name><surname>Ljungars</surname><given-names>A.</given-names></name>
<name><surname>Rimbault</surname><given-names>C.</given-names></name>
<name><surname>S&#x000f8;rensen</surname><given-names>C.V.</given-names></name>
<name><surname>Tulika</surname><given-names>T.</given-names></name>
<name><surname>Wade</surname><given-names>J.</given-names></name>
<name><surname>Wouters</surname><given-names>Y.</given-names></name>
<name><surname>McCafferty</surname><given-names>J.</given-names></name>
<name><surname>Laustsen</surname><given-names>A.H.</given-names></name>
</person-group><article-title>Advances in antibody phage display technology</article-title><source>Drug Discov. Today</source><year>2022</year><volume>27</volume><fpage>2151</fpage><lpage>2169</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2022.05.002</pub-id><pub-id pub-id-type="pmid">35550436</pub-id>
</element-citation></ref><ref id="B42-toxins-17-00055"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palma</surname><given-names>M.</given-names></name>
</person-group><article-title>Epitopes and mimotopes identification using phage display for vaccine development against infectious pathogens</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1176</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11071176</pub-id><pub-id pub-id-type="pmid">37514992</pub-id>
</element-citation></ref><ref id="B43-toxins-17-00055"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Woloschak</surname><given-names>G.E.</given-names></name>
<name><surname>Krco</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Regulation of kappa/lambda immunoglobulin light chain expression in normal murine lymphocytes</article-title><source>Mol. Immunol.</source><year>1987</year><volume>24</volume><fpage>751</fpage><lpage>757</lpage><pub-id pub-id-type="doi">10.1016/0161-5890(87)90058-7</pub-id><pub-id pub-id-type="pmid">3116408</pub-id>
</element-citation></ref><ref id="B44-toxins-17-00055"><label>44.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Kabat</surname><given-names>E.A.</given-names></name>
<name><surname>Wu</surname><given-names>T.</given-names></name>
<name><surname>Gottesman</surname><given-names>K.S.</given-names></name>
<name><surname>Perry</surname><given-names>H.M.</given-names></name>
<name><surname>Foeller</surname><given-names>C.</given-names></name>
</person-group><source>Sequences of Proteins of Immunological Interest</source><edition>5th ed.</edition><publisher-name>US Department of Health and Human Services</publisher-name><publisher-loc>Washington, DC, USA</publisher-loc><publisher-name>Diane Publishing Co.</publisher-name><publisher-loc>Collingdale, PA, USA</publisher-loc><year>1991</year></element-citation></ref><ref id="B45-toxins-17-00055"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilson</surname><given-names>I.A.</given-names></name>
<name><surname>Stanfield</surname><given-names>R.L.</given-names></name>
</person-group><article-title>Antibody-antigen interactions: New structures and new conformational changes</article-title><source>Curr. Opin. Struct. Biol.</source><year>1994</year><volume>4</volume><fpage>857</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1016/0959-440X(94)90267-4</pub-id><pub-id pub-id-type="pmid">7536111</pub-id>
</element-citation></ref><ref id="B46-toxins-17-00055"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crooks</surname><given-names>G.E.</given-names></name>
<name><surname>Hon</surname><given-names>G.</given-names></name>
<name><surname>Chandonia</surname><given-names>J.M.</given-names></name>
<name><surname>Brenner</surname><given-names>S.E.</given-names></name>
</person-group><article-title>WebLogo: A sequence logo generator</article-title><source>Genome Res.</source><year>2004</year><volume>14</volume><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1101/gr.849004</pub-id><pub-id pub-id-type="pmid">15173120</pub-id>
</element-citation></ref><ref id="B47-toxins-17-00055"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jumper</surname><given-names>J.</given-names></name>
<name><surname>Evans</surname><given-names>R.</given-names></name>
<name><surname>Pritzel</surname><given-names>A.</given-names></name>
<name><surname>Green</surname><given-names>T.</given-names></name>
<name><surname>Figurnov</surname><given-names>M.</given-names></name>
<name><surname>Ronneberger</surname><given-names>O.</given-names></name>
<name><surname>Tunyasuvunakool</surname><given-names>K.</given-names></name>
<name><surname>Bates</surname><given-names>R.</given-names></name>
<name><surname>&#x0017d;&#x000ed;dek</surname><given-names>A.</given-names></name>
<name><surname>Potapenko</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id>
</element-citation></ref><ref id="B48-toxins-17-00055"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Slutzki</surname><given-names>M.</given-names></name>
<name><surname>Barak</surname><given-names>Y.</given-names></name>
<name><surname>Reshef</surname><given-names>D.</given-names></name>
<name><surname>Schueler-Furman</surname><given-names>O.</given-names></name>
<name><surname>Lamed</surname><given-names>R.</given-names></name>
<name><surname>Bayer</surname><given-names>E.A.</given-names></name>
</person-group><article-title>Indirect ELISA-based approach for comparative measurement of high-affinity cohesin-dockerin interactions</article-title><source>J. Mol. Recognit.</source><year>2012</year><volume>25</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1002/jmr.2178</pub-id><pub-id pub-id-type="pmid">23108621</pub-id>
</element-citation></ref><ref id="B49-toxins-17-00055"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>R.</given-names></name>
<name><surname>Fang</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>D.</given-names></name>
<name><surname>Lian</surname><given-names>J.</given-names></name>
<name><surname>Fan</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Lin</surname><given-names>W.</given-names></name>
</person-group><article-title>Screening for a single-chain variable-fragment antibody that can effectively neutralize the cytotoxicity of the <italic toggle="yes">Vibrio parahaemolyticus</italic> thermolabile hemolysin</article-title><source>Appl. Environ. Microbiol.</source><year>2012</year><volume>78</volume><fpage>4967</fpage><lpage>4975</lpage><pub-id pub-id-type="doi">10.1128/AEM.00435-12</pub-id><pub-id pub-id-type="pmid">22562997</pub-id>
</element-citation></ref><ref id="B50-toxins-17-00055"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>Q.L.</given-names></name>
<name><surname>Yu</surname><given-names>L.</given-names></name>
<name><surname>He</surname><given-names>Q.L.</given-names></name>
<name><surname>Ge</surname><given-names>L.-P.</given-names></name>
<name><surname>Yang</surname><given-names>X.</given-names></name>
</person-group><article-title>Construction and screening of a phage display library of single chain Fv antibody efficiently from mouse immunized with ovalbumin</article-title><source>China Biotechnol.</source><year>2018</year><volume>38</volume><fpage>25</fpage><lpage>31</lpage></element-citation></ref></ref-list></back><floats-group><fig position="float" id="toxins-17-00055-f001"><label>Figure 1</label><caption><p>Epitope prediction for PLA<sub>2</sub> proteins. (<bold>A</bold>) Predicted epitope (PLA<sub>2</sub>a) containing functional amino acids (in red) for Lys49 PLA<sub>2</sub>. (<bold>B</bold>) Predicted epitope (PLA<sub>2</sub>b) containing functional amino acids (in red) for Asp49 PLA<sub>2</sub>. (<bold>C</bold>) Three-dimensional structure of Lys49 PLA<sub>2</sub> exhibiting that PLA<sub>2</sub>a is accessible. (<bold>D</bold>) Three-dimensional structure of Asp49 PLA<sub>2</sub> displaying that PLA<sub>2</sub>b is accessible.</p></caption><graphic xlink:href="toxins-17-00055-g001" position="float"/></fig><fig position="float" id="toxins-17-00055-f002"><label>Figure 2</label><caption><p>Predicted epitope for SVSP. (<bold>A</bold>) Predicted epitope (SP) containing the functional amino acid &#x0201c;Ser&#x0201d;. (<bold>B</bold>) Simulated 3D structure of SVSP showing the SP is exposed and accessible (<bold>B</bold>).</p></caption><graphic xlink:href="toxins-17-00055-g002" position="float"/></fig><fig position="float" id="toxins-17-00055-f003"><label>Figure 3</label><caption><p>Generation of degenerate PLA<sub>2</sub> and SVSP peptides. Multiple sequence alignments were generated using NCBI Protein BLAST and further analyzed with WebLogo to identify the conserved residues. The final peptides (Lys49, Asp49, and SP) were designed based on the conserved regions, slightly modified, synthesized, and then used for immunizing mice.</p></caption><graphic xlink:href="toxins-17-00055-g003" position="float"/></fig><fig position="float" id="toxins-17-00055-f004"><label>Figure 4</label><caption><p>Animal immunization. A group of five BALB/c mice was immunized with each peptide at a dose of 0.25 mg, followed by three booster injections of 0.25 mg each. Immunogenicity was assessed via ELISA using serum extracted from each mouse. The top three mice (e.g., mice 1, 4, and 5) with the strongest immune responses were selected for the isolation of peripheral blood mononuclear cells (PBMCs) and spleen lymphocytes. Serum was diluted at the following concentrations: 1:2000, 1:4000, 1:8000, 1:16,000, 1:32,000, 1:64,000, and 1:128,000. Negative: serum collected prior to peptide immunization.</p></caption><graphic xlink:href="toxins-17-00055-g004" position="float"/></fig><fig position="float" id="toxins-17-00055-f005"><label>Figure 5</label><caption><p>Generation of scFvs. (<bold>A</bold>) The variable regions of the IgG heavy and kappa chains were individually amplified from the cDNA of PBMC and lymphocytes immunized with Asp49, Lys49, or SP peptides. (<bold>B</bold>) The variable regions of the heavy and kappa chains were linked via a 66-nucleotide linker to generate the scFvs for PLA<sub>2</sub> and SP. (<bold>C</bold>,<bold>D</bold>) Randomly selected 48 plasmid DNAs were analyzed to check for inserts and sequencing.</p></caption><graphic xlink:href="toxins-17-00055-g005" position="float"/></fig><fig position="float" id="toxins-17-00055-f006"><label>Figure 6</label><caption><p>Amino acid sequence alignment of scFvs. The upper panel (PLA<sub>2</sub>) shows PLA<sub>2</sub> scFv sequence alignment, while the lower panel (SP) reveals the SP scFv sequence alignment. The complementarity-determining regions (CDR) and framework regions (FR) were labeled in grey and connected through a linker underlined to make the (V<sub>H</sub>-linker-V<sub>L</sub>) configuration.</p></caption><graphic xlink:href="toxins-17-00055-g006" position="float"/></fig><fig position="float" id="toxins-17-00055-f007"><label>Figure 7</label><caption><p>ELISA for detection of peptide-scFv interactions. Half of a 96-well plate was coated with Asp49 peptide (<bold>A</bold>), while the other half was coated with SP peptide (<bold>B</bold>). (<bold>C</bold>) A summary of binding affinity. Each of the 48 sequenced PLA<sub>2</sub> and SP scFvs clones was incubated with Asp49 and SP peptide, respectively. Anti-GST primary antibody and secondary antibody conjugated with HRP were used for detection in the ELISA. Arrows indicate positive interactions.</p></caption><graphic xlink:href="toxins-17-00055-g007" position="float"/></fig><table-wrap position="float" id="toxins-17-00055-t001"><object-id pub-id-type="pii">toxins-17-00055-t001_Table 1</object-id><label>Table 1</label><caption><p>Primers for amplification of heavy, kappa, and scFv.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Sequences</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">VhF</td><td align="left" valign="middle" rowspan="1" colspan="1">V<sub>H</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">GTKAMKCTRRWRGAGTCTGG</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VhR</td><td align="left" valign="middle" rowspan="1" colspan="1">V<sub>H</sub></td><td align="left" valign="middle" rowspan="1" colspan="1"><underline>TCCACCTGAGGAGAC</underline>TGGATAGACHGATGGGGSTGT</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VkF</td><td align="left" valign="middle" rowspan="1" colspan="1">V<sub>L</sub></td><td align="left" valign="middle" rowspan="1" colspan="1"><underline>TCGGACATCGAGCTC</underline>CRMRDTVTKCTSWHHCARWCW</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VkR</td><td align="left" valign="middle" rowspan="1" colspan="1">V<sub>L</sub></td><td align="left" valign="middle" rowspan="1" colspan="1">GATRGATACARTKKGTGCAGCATC</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Linker</td><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1"><underline>gtctcctcaggtgga</underline>ggcggttcaggcggaggtggctctggcggtggcgga<underline>tcggacatcgagctc</underline></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">scFv-EcoRI</td><td align="left" valign="middle" rowspan="1" colspan="1">scFv</td><td align="left" valign="middle" rowspan="1" colspan="1">GGT<italic toggle="yes">GAATTC</italic>GTKAMKCTRRWRGAGTCTGG</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">scFv-XhoI</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">scFv</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGT<italic toggle="yes">CTCGAG</italic>TCATTAGATRGATACART</td></tr></tbody></table><table-wrap-foot><fn><p>Underlined sequences are for in-fusion ligation with linker, and restriction sites are italicized.</p></fn></table-wrap-foot></table-wrap></floats-group></article>